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Recombinant tissue-type plasminogen activator (r&PA) from cultures of a genetically manipulated Bowes 
melanoma cell line (TRBM6) was purified in batches of average volume 451 using an autoclavable, reusable, 
continuous chromatography system comprising zinc chelate-Sepharose CL4B and lysine-Sepharose CL4B. 
After eight successive purifications the r&PA was ultrafiltered to yield a preparation containing 4.9 mg pro- 
tein/ml and 2.7 x lo6 IU/ml. Analysis by SDS-polyacrylamide gel electrophoresis followed by staining with 
Coomassie brilliant blue R250 showed major protein bands at M, = 63000 and 65000, most of the material 
was in the l-chain form. The potential usefulness of a simple, rapid continuous chromatography system that 
can be operated under aseptic onditions is discussed. 
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1. INTRODUCTION 
Plasminogen activators are attracting con- 
siderable interest for use in the treatment of acute 
myocardial infarction [l-3]. The evaluation of one 
of these activators, tissue-type plasminogen ac- 
tivator (t-PA), aIone, or in comparison with other 
second generation activators such as the 
anisoylated plasminogen/streptokinase activator 
complex (APSAC or BRL 26921 [4]), requires 
large supplies of purified material suitable for use 
in the clinic. Numerous publications have detailed 
purification procedures for t-PA. The most fre- 
quently used affinity matrices for this purpose are 
zinc chelate-Sepharose 4B and concanavalin A- 
Sepharose 4B [5-71, immunoadsorbents [8-lo] 
and arginine- [8,9] or lysine8epharose 4B [lo- 121. 
Unfortunately, these purification regimes often in- 
volve a concentration step between columns (e.g. 
[5-g]) or are time consuming, for example because 
of low flow rates (C 10 cm-h-‘) during 
chromatography [6,9]. Furthermore, because the 
support for the affinity ligand is generally non- 
crosslinked agarose the system cannot easily be 
operated aseptically. In addition, the applicability 
of these systems to the large-scale purification of 
recombinant -PA (r&PA) has not been evaluated. 
During studies on the rt-PA molecule we 
developed a simple, rapid purification process 
utilising continuous chromatography on zinc 
chelate-Sepharose CL4B and lysine-Sepharose 
CL4B. An additional advantage of this system is 
that both matrices and all the buffers employed 
can be sterilised easily. 
2. MATERIALS AND METHODS 
2.1. Materials 
The recombinant Bowes melanoma cell line, 
TRBM6, has been described previously [ 131. 
Eagles minimal essential medium, newborn calf 
serum and Nunc culture flasks were purchased 
from Gibco, Paisley, Scotland. The stainless steel 
filter (10 pm pore size) was from Pall Process 
Filtration, Portsmouth, England. Zinc chelate- 
Sepharose CL4B [14] and lysine-Sepharose CL4B 
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[15], were kindly supplied by Drs T. J. Grinter and 
K.T. Veal. Ultrafiltration membranes (YMlO) 
were obtained from Amicon, Stonehouse, 
England. The sources of the other reagents have 
been described [ 161. 
2.2. Cell culture 
TRBM6 cells were cultured and were harvested 
for rt-PA as described before [16]. The serum-free 
harvest medium was collected aseptically into a 
polypropylene carboy. Cells or cell debris were 
removed by passage through a stainless teel filter. 
2.3. Purification 
The first purification matrix was zinc chelate- 
Sepharose CL4B. The column was equilibrated 
with 0.02 M phosphate, 0.15 M sodium chloride, 
0.01% Tween 80, pH 7.4 (PBS/TW), and then the 
filtered harvest medium was passed through. The 
column was immediately washed with (i) 
PBS/TW, (ii) 0.02 M Tris, 1 .O M sodium chloride, 
0.01% Tween 80, pH 7.4, (iii) 0.02 M phosphate, 
0.3 M sodium chloride, 0.01% Tween 80, pH 7.4, 
and was finally eluted with (iv) 0.02 M phosphate, 
0.3 M sodium chloride, 0.05 M imidazole, 0.01% 
Tween 80, pH 7.4. The eluate of the imidazole- 
containing buffer was passed directly onto a col- 
umn of lysine-Sepharose CL4B that had been 
equilibrated previously in PBS/TW. After the 
equivalent of two bed volumes of the zinc chelate- 
Sepharose CL4B column had passed through the 
1ysineSepharose CL4B column the flow from the 
former was stopped. The lysine-Sepharose CL4B 
column was then washed sequentially with (i) 
PBS/TW, (ii) 0.02 M Tris, 0.5 M sodium chloride, 
0.01% Tween 80, pH 7.4, and (iii) 0.02 M Tris, 
0.5 M sodium chloride, 0.5 M L-arginine, 0.01% 
Tween 80, pH 7.4. All stages of the 
chromatography were carried out at 5-10°C. The 
velocity of flow was varied as follows. The applica- 
tion of the harvest medium to the zinc chelate- 
Sepharose CL4B column was at 32 cm-h-‘. All 
elutions were at 100 cm. h-l. The volume of affini- 
ty matrix used in each purification was on the 
following basis: 10 1 harvest medium; 200 ml zinc 
chelate-Sepharose CL4B; 40 ml lysine-Sepharose 
CL4B. Height/diameter atios of the columns were 
in the range 3-8. All buffers and affinity matrices 
used were sterilised (121”C/15 min). 
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2.4. Concentration 
After eight successive purifications individual 
pools of rt-PA were thawed and mixed and were 
concentrated using stirred-cell ultrafiltration 
(YMlO). The ultrafiltered retentate was stored at 
- 40°C. 
2.5. Miscellaneous 
SDS-polyacrylamide gel electrophoresis (SDS- 
PAGE), fibrin zymography, a colorometric pro- 
tein analysis and the assay for amidolytic activity 
were carried out as described previously [16]. Pro- 
tein content was also determined, after acid 
hydrolysis of the product, by amino acid analysis 
using the Waters PICO. TAG system [17]. 
Fibrinolytic activity was measured essentially as 
before [18]; calibration was against the interna- 
tional standard for t-PA, Lot 83/517. 
3 .RESULTS 
Serum-free harvest medium from cultures of 
TRBM6 cells was collected and passed batchwise 
through a stainless-steel filter to remove cell 
debris. This filtration usually took place at 50 l/h 
but occasionally was increased to 200 l/h ap- 
parently without detrimental effect. The rest of the 
purification, on the zinc chelate-Sepharose CL4B 
and lysine-Sepharose CL4B columns, was carried 
out in series. Filtered harvest medium could be 
pumped onto the column of zinc chelate-Sepharose 
CL4B at a flow rate of 200 cm-h-‘. However, this 
application was generally carried out overnight, at 
a reduced velocity. The column was washed to 
remove contaminating proteins as described in sec- 
tion 2. Recombinant -PA was desorbed from the 
matrix using 0.02 M Tris, 0.3 M sodium chloride, 
0.05 M imidazole, 0.01% Tween 80, pH 7.4. The 
eluate containing the rt-PA was diverted directly 
onto the column of immobilised lysine. The veloci- 
ty of flow was adjusted to 200 cm-h-’ (of surface 
area of the 1ysineSepharose CL4B column). Under 
these conditions virtually all the rt-PA activity ad- 
sorbed to the 1ysineBepharose CL4B column. The 
rt-PA was subsequently desorbed by a buffer con- 
taining 0.5 M L-arginine and the eluate was frac- 
tionated. 
The most active fractions were identified using a 
rapid microtitre plate-based assay employing the 
chromogenic substrate S-2288 and were pooled 
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Table 1 
Recovery of rt-PA from eight individual purifications, totalling 360 1 harvest 
medium, after the various stages of the process 
Solution 
analysed 
Fibrin plate Proteina Specific activity 
activity (mg) (IU/mg protein) 
(IU x lo-“) [Vo] 
Harvest medium 
(pre filtration) 202 11001 13400 15 100 
‘Active fractions’ 
from zinc chelate- not 
Sepharose CL4B 143 [ 711 determined - 
Active fractions 
from lysine- 
Sepharose CL4B 169 1 841 356 475000 
Ultrafiltered retentate 176 1 871 371 474000 
(319)b (552000)b 
a Protein figures were derived using the calorimetric assay described in 
section 2 
b Corresponding figures using protein content determined by amino acid 
analysis 
The activity of the ‘active fractions’ from the zinc chelate-Sepharose CL4B 
column was based on assay of a sample collected continuously during 
application to the lysine-Sepharose CL4B column 
and stored at -40°C. Most of the activity was in 
a volume equivalent o half the bed volume of the 
immobilised lysine column but generally the pool 
was made of fractions totalling twice this volume. 
Recovery of fibrinolytic activity during the 
purification stages was 70% or better (table 1). 
After several purification runs individual pools 
were thawed and mixed and were concentrated by 
stirred-cell ultrafiltration using membranes with a 
nominal cut-off of A4,lOOOO. Loss at this stage was 
minimal (table 1). The ultrafiltered retentate had a 
protein content, based on amino acid analysis, of 
4.9 mg/ml and, therefore, the specific activity of 
the rt-PA was 552000 IU/mg protein. Despite the 
absence of aprotinin in the harvest medium or in 
any of the purification buffers the r-t-PA in the 
purified pool was mainly l-chain (fig. 1). It was ali- 
quoted and stored at -40°C for further studies. 
SDS-PAGE followed by fibrin zymography of the 
final product revealed a major band at M =63000 
(not shown). 
4. DISCUSSION 
The treatment of acute myocardial infarction us- 
ing t-PA [l] has been aided by its successful isola- 
tion on a large scale. Although several arge-scale 
procedures for the purification of t-PA have been 
published [6,7,9,10] none has been particularly 
rapid or has used systems capable of aseptic opera- 
tion. We believe that the simple and rapid con- 
tinuous purification process described here, as well 
as being applicable to rt-PA, has significant advan- 
tages over previously described large-scale pro- 
cedures. In particular, the use of crosslinked 
agarose as the support for the immobilised ligands 
allows not only both matrices to withstand 
autoclaving but also attainment of high flow rates. 
At such flow rates the overall purification pro- 
cedure was rapid; this is probably one reason why 
there was no need, in contrast to a previous report 
[5], to use aprotinin in either the harvest medium 
or the purification buffers in order to obtain main- 
15 
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Fig. 1. SDS-PAGE of purified rt-PA. Ultrafiltered 
retentate was diluted in 0.125 M Tris, 0.1% SDS, pH 
6.8, in the presence or absence of 2-mercaptoethanol 
(5%. v/v) and analysed as described in section 2. The 
stained gel is shown. Lanes marked M are marker 
proteins; lanes marked T are rt-PA. 
ly l-chain material. The reusability of both 
matrices was an additional advantage (not shown). 
The purity of the product determined by SDS- 
PAGE followed by staining for protein compared 
well with that from other procedures. Also, the 
specific activity of the product, 552000 IU/mg 
protein, compared with a figure of 270000 to 
340000 IU/mg described elsewhere [19]. (It is 
more difficult to make further comparisons owing 
to the use by other authors of the urokinase inter- 
national standard.) 
Further studies on the rt-PA molecule in this 
laboratory have required more concentrated 
material. Although we have achieved this by 
discontinuous ultrafiltration we cannot see any 
reason why, on larger scale operations, the pro- 
cedure could not be carried out in line. An alter- 
native to this approach is the elution of rt-PA from 
lysine-Sepharose using a volatile buffer such as 
0.01 M formate [20], followed by lyophilisation. 
In either case the requirement for further formula- 
tion into a product suitable for the clinic is likely 
to be minimal. The purification process described 
here has been in routine use for many months, pro- 
viding us with significant amounts of rt-PA for 
research evaluation both in vitro and in vivo. 
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